Calidi Biotherapeutics Q2 2026 net loss narrows to $4.2M; FDA agrees on CLD-401 path

Calidi Biotherapeutics, Inc.

Net loss attributable to common stockholders: $4.2M ($2.94/share) vs $5.7M ($31.75/share) in Q2 2025, adjusted for 1-for-16 reverse split.
G&A expenses cut 48% to $1.6M from $3.1M; R&D flat at $2.6M.
Cash and restricted cash $4.3M at June 30, 2026 vs $5.8M at Dec 31, 2025.
FDA pre-IND feedback for CLD-401 supports first-in-human study; first patient dosing targeted Q1 2027.
Added Corsee Sanders, Ph.D. (ex-Genentech/Roche, Celgene) to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.